HighBeam QuickSearch
Get direct access to articles and research when you
add HighBeam to your browser's search toolbar.
|
-
-
FIMALAC announces completion of the divestment of ENGELHARD-CLAL.
-
Business Wire; Jan 7, 2004; 426 Words
...contribution to FIMALAC's consolidated net...completed the sale of CLAL-MSX, a wholly-owned...some EUR43 million, CLAL-MSX's recurring income...EUR10.5 million to CLAL-MSX). These two transactions...line with FIMALAC's goal of withdrawing...
-
-
Fimalac: First-Half 2004 Results.
-
Business Wire; Oct 7, 2004; 700+ Words
PARIS -- Fimalac's (OTC:FMLCF)(BOURSE...of LBC in early May and of CLAL-MSX at year-end 2003, as well...the divestment of LBC and CLAL-MSX and to the impact of...reflects the impact of Facom's turnaround program underway...
-
-
Fimalac S.A.
-
International Directory of Company Histories; 700+ Words
...Fimalac ’ s 1999 revenues. Fimalac ’ s third major area of...which include its CLAL-MSX subsidiary and the related Engelhardt-CLAL joint venture, which...the world ’ s number two provider...
-
-
Fimalac: Revenues for the First Nine Months of 2004 up 3.9% Like-for-Like.
-
Business Wire; Oct 25, 2004; 518 Words
PARIS -- Fimalac's (OTC:FMLCF) (BOURSE...to the deconsolidation of CLAL-MSX and LBC, which were divested...Fitch's revenues for the nine-month...reflecting the company's robust third quarter performance...
-
-
Fimalac: First-Half 2004 Sales: Up 3.7% Like-for-Like.
-
Business Wire; Jul 28, 2004; 480 Words
...sales were down 7.8%, due mainly to the exclusion of CLAL-MSX and LBC, which were divested in December 2003 and May 2004...Beissbarth sales rose 9.5%* to EUR 81.0 million. Cassina's sales came to EUR 58.6 million, down by a modest 1...
-
-
Fimalac First Quarter Revenues: Up 3.3% Like-for-Like.
-
Business Wire; Apr 28, 2004; 530 Words
...effect of the end-2003 divestment of Clal-Msx. (In EUR millions) 1st 1st quarter...to EUR 36.9 million. Cassina's sales contracted 4.2% (*) to EUR 29.1 million. LBC's sales amounted to EUR 29 million, a...
-
-
NewCo News Biokine Gets $1.2M to Kick Off Phase I/II Trial with CXCR4 Drug.
-
BIOWORLD Today; Mar 18, 2009; ; 700+ Words
...Israel -- brings Biokine's fundraising total to slightly...provided by the company's founders and the Weizmann...as Series A funding from Clal Biotechnology Industries...myeloma and non-Hodgkin's lymphoma patients. (See...trial with CXCR4 inhibitor MSX-122. But Peled explained...
|
|